Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS) Topline Phase 2 data from both the AD and HS trials expected in the first half of 2025 WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.

特应性皮炎（AD）试验是第二个KT-474 2期临床试验，该试验于本季度开始招募患者，此前在2025年12月7日，马萨诸塞州沃特敦，2023年12月7日，AD和HS试验的Topline 2期试验数据均来自Kymera Therapeutics，Inc。

(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi.

（纳斯达克：KYMR），一家临床阶段的生物制药公司，利用靶向蛋白质降解（TPD）开发了一类新的小分子药物，今天宣布，第一名患者已经在随机2期临床试验（ADVANTA）中服用，该试验评估了AD中的KT-474（SAR444656），在与赛诺菲的合作下产生了1500万美元的里程碑式付款。

The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, which generated a $40 million milestone payment under the terms of the collaboration.

第二阶段研究将评估KT-474（一种一流的研究性IRAK4降解剂）与安慰剂相比在中重度AD成年患者中的疗效和安全性。赛诺菲正在AD和HS中进行第二阶段KT-474研究，并于2023年10月给第一名HS患者服用，根据合作条款产生了4000万美元的里程碑付款。

Study completion dates for both trials are projected in the first quarter of 2025. “The initiation of dosing in the second Phase 2 trial of KT-474 reinforces the potential of degrading IRAK4 in the treatment of multiple immunological and inflammatory diseases, and the promise of TPD to offer patients with complex inflammatory diseases a new way to manage their disease,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics.

两项试验的研究完成日期预计在2025年第一季度。Kymera Therapeutics创始人、总裁兼首席执行官内洛·梅诺尔菲（Nello Mainolfi）博士说：“KT-474第二阶段试验开始给药，增强了降解IRAK4治疗多种免疫和炎症性疾病的潜力，TPD有望为患有复杂炎性疾病的患者提供一种治疗疾病的新方法。”。

“Our focus has always been on genetically validated targets within pathways with clear clinical validation and where TPD offers the best or the only path to creating an effective treatment, and we believe our IRAK4 degrader has the potential to offer AD patients a w.

“我们的重点一直是在具有明确临床验证的途径中进行基因验证的目标，TPD是创造有效治疗的最佳或唯一途径，我们相信我们的IRAK4降解剂有可能为AD患者提供w。